Brief: Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint
05/06/2026 21:45
BRIEF-Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint June 6 (Reuters) - Zealand Pharma A/S ZELA.CO:
ZEALAND PHARMA: PETRELINTIDE LED TO MEAN REDUCTIONS IN BODY WEIGHT FROM BASELINE TO WEEK 42 OF UP TO 10.7% VERSUS 1.7% FOR PLACEBO
ZEALAND PHARMA: PHASE 2 ZUPREME-1 TRIAL MET ITS PRIMARY ENDPOINT
ZEALAND PHARMA: PHASE 2 ZUPREME-1 TRIAL SHOWS CLINICALLY MEANINGFUL, DOUBLE-DIGIT WEIGHT LOSS IN PARTICIPANTS THROUGH WEEK 42
ZEALAND PHARMA: PHASE 3 TRIALS FOR CHRONIC WEIGHT MANAGEMENT PLANNED FOR INITIATION IN H2 2026
ZEALAND PHARMA: ONLY 1.5% OF PARTICIPANTS DISCONTINUED PETRELINTIDE DUE TO GASTROINTESTINAL AES, NO UNEXPECTED SAFETY FINDINGS
Further company coverage: ZELA.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza